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Changes to the West Nile Virus Genome Have
Increased Its Virulence in Birds and Allowed Rapid
Spread
West Nile virus (WNV) is a small, enveloped, mosquito-
transmitted, positive-stranded RNA virus of the Flaviviridae
family. This virus is related to other arthropod-borne viruses that
cause human disease globally, including dengue, yellow fever, and
Japanese encephalitis viruses. WNV cycles in nature primarily
between Culex mosquitoes and birds, but also infects human,
horses, and other vertebrates. Over the latter half of the 20th
century, outbreaks of WNV infection have been reported in
Europe, Asia, and Australia. In 1999, WNV was introduced into
the Western Hemisphere in New York City.
Early during the WNV epidemic in the United States, it became
apparent that certain species of birds, including crows, blue jays,
and ravens, were vulnerable to lethal infection. This phenotype
was not described in prior outbreaks in other parts of the world.
Genome sequencing combined with reverse genetic approaches
has provided some insight as to why WNV became virulent for
some avian species. Although the exact molecular mechanism
remains uncertain, a single amino acid change in the NS3 helicase
in North American WNV isolates gene associates with pathogen-
esis in crows [1].
After its entry into North America, there was an initial period of
sequence conservation among strains. However, by 2002, two
sequence subtypes were detected, one of which differed in the
envelope (E) protein at amino acid 159 (WNV 2002). WNV 2002
has emerged as the dominant WNV genotype in North America.
Experiments in mosquitoes have begun to explain why this strain
displaced WNV 1999 and promoted the rapid spread across the
continent. The change at residue 159 allows greater viral
replication in the mosquito at higher temperatures, which
translates into higher transmission of the virus to birds, the
natural vertebrate host of WNV [2,3]. Thus, a single amino acid
change in WNV has led to rapid geographic expansion and
increased intensity of transmission.
Paradoxes of the Humoral Immune Response
against WNV
Humoral immunity limits WNV dissemination, as animals
lacking antibodies develop high-grade viremia, early dissemination
into the brain, and uniform mortality [4]. The envelope E
glycoprotein is the major surface structural protein on the virion
and the principal antigen that elicits neutralizing antibodies; as
such, it is a primary target for vaccine development. New studies
suggest and explain why the level of neutralizing antibodies in
serum may not always correlate with protection against WNV.
WNV virions incorporate 180 E proteins on their surface. The
E proteins of newly synthesized immature WNV are organized
into trimeric spikes composed of pre-membrane (prM) and E
protein heterodimers. During egress, immature virions undergo a
maturation step in which a furin-like protease cleaves prM,
resulting in a reorganization of E proteins into a distinct
homodimeric array [5]. As complete maturation is not required
for infectivity, WNV virions can be heterogeneous with respect to
the level of prM on their surface. In theory, mature, partially
mature, and mostly immature virions may be differentially
recognized and neutralized by antibodies. Recent experiments
establish that virion maturation impacts the sensitivity of WNV to
antibody neutralization [6]. Antibodies that target the virus fusion
peptide, which comprise a major component of the human
antibody response following WNV infection or vaccination, do not
neutralize the fully mature form of the virion.
Interestingly, some poorly neutralizing human antibodies
against E may still be protective in vivo (M. Vogt, M. Throsby,
and M. Diamond, unpublished data), presumably due to
interactions with complement and/or Fc-c receptors. Further-
more, NS1, a non-structural glycoprotein that is absent from the
virion but expressed on the surface of infected cells, elicits non-
neutralizing protective antibodies that inhibit infection through
both Fc-c receptor–dependent and -independent mechanisms [7].
Although both neutralizing and non-neutralizing antibodies
contribute to humoral protection against WNV infection and
possibly other flaviviruses, current vaccine programs judge the
efficacy of the humoral response primarily on the magnitude of
neutralizing antibodies measured in serum. The studies outlined
above suggest that improved correlations with protection in vivo
may be achieved if the maturation state of the virion, the
functional profile of anti-NS1 antibodies, and effector mechanisms
of antibodies are considered.
A Protective Cellular Immune Response against
WNV in the Brain
For many encephalitic viruses, the cellular immune response in
the central nervous system (CNS) can be pathologic, as injury to
neurons or glial cells causes irreversible loss of function and death
[8]. However, cellular immunity is absolutely required for
clearance of infection by virulent North American WNV isolates.
Mice deficient in CD4
+ or CD8
+ T cells develop persistent WNV
infection in the brain [9,10], and humans with hematological
malignancies and impaired T cell function are at increased risk of
Citation: Diamond MS (2009) Virus and Host Determinants of West Nile Virus
Pathogenesis. PLoS Pathog 5(6): e1000452. doi:10.1371/journal.ppat.1000452
Editor: Hiten D. Madhani, University of California San Francisco, United States of
America
Published June 26, 2009
Copyright:  2009 Michael S. Diamond. This is an open-access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
Funding: The author received no specific funding for this article.
Competing Interests: The author has declared that no competing interests
exist.
* E-mail: diamond@borcim.wustl.edu
PLoS Pathogens | www.plospathogens.org 1 June 2009 | Volume 5 | Issue 6 | e1000452PLoS Pathogens | www.plospathogens.org 2 June 2009 | Volume 5 | Issue 6 | e1000452neuroinvasive WNV infection and poor outcome [11]. WNV-
specific CD8
+ T cells secrete inflammatory cytokines and lyse
virus-infected neurons through perforin- and Fas ligand–depen-
dent mechanisms, whereas CD4
+ T cells sustain WNV-specific
CD8
+ T cell responses in the CNS that enable viral clearance [10].
This lytic and potentially destructive activity of WNV-specific
CD8
+ T cells in the brain is paradoxically protective because of the
urgent need to limit replication of a highly cytopathic virus in
neurons. Consistent with this, if mice are infected with a less
pathogenic isolate of WNV, the CD8
+ T cell response can be
detrimental and cause excessive immunopathogenesis and injury
[12].
West Nile Virus and IFN: Regulation and Counter-
Regulation
The interferon (IFN) response is an essential host defense
program that limits infection of many families of RNA and DNA
viruses. IFN-a and -b are produced during the earliest stages of
WNV infection after host cell recognition of viral RNA.
Mammalian cells detect WNV viruses and induce IFN by
recognizing single (ssRNA) or double-stranded (dsRNA) viral
RNA through the endosomal Toll-like receptors 3 and 7 (TLR3
and TLR7), and the cytoplasmic proteins retinoic acid-inducible
gene I (RIG-I) and melanoma-differentiation-associated gene 5
(MDA5). Mice with genetic defects in any of these individual RNA
sensors, the receptor for IFN-a and -b, or constituents of its
signaling cascade (e.g., STAT1) show markedly enhanced viral
burden in tissues, which leads to rapid lethality.
Although IFN restricts infection, WNV has evolved counter-
measures to limit its efficacy. Indeed, WNV is resistant to the
antiviral effects of IFN in cell culture once infection is established.
This may explain the relatively narrow therapeutic window for
IFN administration that has been observed in animal models or
humans infected with WNV [13]. WNV attenuates IFN function
at multiple steps of the induction (Figure 1A) and signaling
(Figure 1B) cascade. (a) The WNV NS2A protein inhibits IFN-b
gene transcription [14]. (b) WNV E and NS1 proteins indepen-
dently inhibit IFN-b transcription in response to dsRNA [15,16].
(c) Pathogenic WNV strains evade IRF-3-dependent signals
without actively antagonizing the host defense signaling pathways
[17]. This provides a kinetic advantage to elude the IFN response
at early times after infection. WNV also targets the JAK-STAT
proteins, essential elements of the IFN signaling pathway, to
prevent the induction of antiviral genes. Thus, even when type I
IFN is produced, it may not achieve its inhibitory effect. (d) WNV
interferes with phosphorylation of JAK1 and Tyk2 [18]. (e) WNV
infection actively promotes re-localization of cholesterol, which
diminishes the formation of cholesterol-rich lipid rafts in the
plasma membrane and attenuates the IFN signaling [19]. (f) The
NS4B of WNV partially blocks STAT1 activation and IFN-
stimulated gene (ISG) induction [20].
The Genetic Basis of Risk of Human WNV Infection
Is Beginning to Be Understood
Most (,80%) human WNV cases develop without significant
symptoms. Among clinically apparent cases, many experience a self-
limited,althoughattimesdebilitating,febrileillness.AsubsetofWNV
cases progress to paralysis, meningitis, and/or encephalitis.
Two human genes have been identified as susceptibility loci for
WNV infection. (1) CCR5. Experiments in animals had
established that chemokines direct leukocytes to the brain to clear
WNV from infected neurons. In mice, a genetic deficiency of the
chemokine receptor CCR5 was associated with depressed
leukocyte trafficking, increased viral burden, and enhanced
mortality [21]. Interestingly, analogous genetic deficiencies (e.g.,
CCR5D32, a deletion in the CCR5 gene) are associated with WNV-
induced disease in humans [22]. Although individuals that are
homozygous for the CCR5D32 allele represent about ,1% of the
general United States population, 4%–8% of individuals with
laboratory-confirmed symptomatic WNV infection were homozy-
gous for the mutant allele. Thus, CCR5 functions as an essential
host factor to resist neuroinvasive WNV infection, which may have
implications for the use of CCR5 antagonists in HIV therapy. (2)
OAS.In certainmouse strains,susceptibilityto flaviviruses,including
WNV, maps to a truncated isoform of the 29 59 oligoadenylate
sythetase (OAS1b) gene, a member of an IFN-regulated gene family
involved in degradation of viral RNA. A recent study suggests that a
hypomorphic allele of the human ortholog OAS1 is associated with
bothsymptomaticandasymptomaticWNVinfection[23].Thisdata
suggests that inhumans, OAS1 isa geneticrisk factor for initial WNV
infection, although not for disease severity.
Conclusions
Pathogenesis and host immune response studies with model
viruses (e.g., lymphocytic choriomeningitis, polio, herpes simplex,
and mouse hepatitis viruses) created an impression that the virus–
host interface is remarkably conserved, and the paradigms
generated for one pathogen are readily transferable to another.
However, the complexity of individual viruses with respect to
enzootic cycles, the host–pathogen–vector interface, cellular
tropism, structural diversity, ability to induce injury, and immune
system recognition and evasion has established that the exception
is often the rule: the host responds differently to control individual
viruses. Studies with WNV are continuing to educate us as to the
extent of this complexity. Hopefully, these lessons will translate
into novel therapeutics and vaccines against WNV and possibly,
closely related pathogenic flaviviruses.
Figure 1. IFN signaling and mechanisms of evasion by WNV. (A) Infection by WNV produces dsRNA intermediates within the cytoplasm that
display motifs recognized by the RIG-I and MDA5 helicases. Binding of viral RNA promotes an interaction with IPS-1 that results in recruitment of
signaling proteins (e.g., NEMO and TRAF3) that lead to activation of IRF-3 and NF-kB. These factors translocate to the nucleus and bind to the
promoter region of the IFN-b gene, leading to transcription and translation. In some cells, TLR3 and TLR7 in endosomes recognize dsRNA and ssRNA
motifs, leading to recruitment of cytoplasmic adaptor molecules (MyD88 and TRIF), which initiate signaling cascades that activate IRF-3, IRF-7, and
NF-kB, resulting in IFN-b gene transcription. Mechanisms of evasion by WNV include the following: (a) reduction in IFN-b gene transcription by the
viral NS2A protein; (b) impairment of RIP-1 signaling by high mannose carbohydrates on the structural E protein and attenuation of TLR3 signaling by
NS1; and (c) a delay in recognition of WNV RNA by RIG-I. (B) Secretion of IFN by WNV-infected cells results in autocrine and paracrine signaling
through the heterodimeric receptor for IFN-a and b (IFNAR). Binding by IFN results in activation and tyrosine phosphorylation of JAK family members
(JAK1 and Tyk2) and the cytoplasmic tail of the IFN-abR. This promotes recruitment of the STAT1 and STAT2, which themselves become
phosphorylated by the JAKs. Phosphorylated STAT1 and STAT2 proteins heterodimerize, associate with IRF-9, and translocate to the nucleus, where
they bind IFN-stimulated response element (ISRE) sequences to induce expression of hundreds of ISGs. Mechanisms of evasion by WNV include (d)
blockade of phosphorylation of Tyk2 and JAK1 by NS5; (e) down-regulation of the IFNAR through virus-induced redistribution of cellular cholesterol;
and (f) attenuation of STAT signaling by NS4B.
doi:10.1371/journal.ppat.1000452.g001
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